New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 11, 2013
06:40 EDTNSTGNanoString upgraded to Outperform from Neutral at RW Baird
Baird upgraded NanoString following the announcement that several leading U.S. clinical labs and cancer centers will offer Prosigna breast cancer diagnostic tests in Q1 2014. The firm believes the initial customer wave represents over 50% of potential volumes and raised its price target to $18 from $12.
News For NSTG From The Last 14 Days
Check below for free stories on NSTG the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 7, 2014
07:34 EDTNSTGNanoString launches nCounter PanCancer Pathways Panel
NanoString Technologies announced the launch of the nCounter PanCancer Pathways Panel, a highly-multiplexed, digital gene expression assay that offers a way for translational researchers to investigate cancer biology across all major cancer pathways. A growing body of research has demonstrated that a pathway-based approach to the analysis of gene expression provides a framework for understanding the changes between the biology of different cancers and cancer subtypes. From a single tube, the PanCancer Pathways Panel simultaneously analyzes of all of the key cancer pathways: PI3K, STAT, MAPK, TGF, Notch, Hedgehog, Wnt, Apoptosis, Cell Cycle, RAS, Chromatin Modification, Transcriptional Regulation and DNA Damage Control. Processing samples on the nCounter Analysis System takes just 15 minutes of hands-on time and generates reproducible data, representing a solution for studying cancer.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use